peptide-phi has been researched along with Asthma* in 4 studies
3 review(s) available for peptide-phi and Asthma
Article | Year |
---|---|
[The nonadrenergic, noncholinergic neuropeptide system and asthma].
An understanding of the non adrenergic non cholinergic nervous system and its implication in the pathogenesis of asthma would benefit by the identification and localisation of the numerous natural bioactive peptides at the pulmonary level. In the past few years two components of the non adrenergic non cholinergic nervous system have been characterised. A bronchodilator component which would be mediated by "vaso-active intestinal peptide" (VIP) and the "peptide histidine methionine" (PHM). A broncho-constrictor component which would be mediated by the neurokinins (substance P (SP), neurokinin A (NKA) and the "calcitonin gene related peptide" (CGRP)). These neuropeptides, in vitro as well as in vivo, have effects which are not limited to the regulation of bronchial smooth muscle tone. In effect, they may intervene in the regulation of vascular tone, in the production of mucous and in the expression of immediate hypersensitivity reactions at pulmonary level. Several neuropeptides are present or co-exist with classical neurotransmitter in the afferent nerve endings of the pulmonary efferents. This co-existence of several neurotransmitters in the same nervous fibres raised the questions as to their interactions at the pre or post synaptic level. The implication of these neuropeptides in the pathogenesis of asthma rests on numerous experimental arguments. This recent aspect in the pathophysiology of asthma allows us to hope for new therapeutic approaches. Topics: Asthma; Autonomic Nervous System; Bronchi; Humans; Muscle, Smooth; Neuropeptides; Neurotransmitter Agents; Peptide Fragments; Peptide PHI; Protein Precursors; Respiratory Hypersensitivity; Vasoactive Intestinal Peptide | 1988 |
Non-adrenergic non-cholinergic neural control of human airways.
In addition to classical cholinergic and adrenergic neural mechanisms, a third division of autonomic control has been recognised in human airways. Non-adrenergic inhibitory nerves are the dominant inhibitory neural pathway in human airway smooth muscle and there is increasing evidence that VIP and a related peptide, PHM, may be the neurotransmitters. These peptides are probably cotransmitters of acetylcholine in the airways and may modulate cholinergic effects. A defect in this system could occur in asthma because inflammation may more rapidly inactivate these neurotransmitter peptides. Non-cholinergic excitatory nerves have also been described in animal airways, although their existence in human airways is less certain. The neurotransmitter may be substance P or a related peptide neurokinin A, which could be released by axon reflex. Another peptide, calcitonin gene-related peptide, is colocalized with substance P and appears to be much more potent in human airways. Non-adrenergic non-cholinergic mechanisms may also regulate mucus secretion and the bronchial microvasculature. The role of this nervous system in health and disease is still uncertain as there are no specific blockers available. Topics: Acetylcholine; Asthma; Autonomic Nervous System; Calcitonin Gene-Related Peptide; Humans; Lung; Muscle, Smooth; Nerve Tissue Proteins; Neurons; Neurotransmitter Agents; Peptide PHI; Peptides; Respiratory Physiological Phenomena; Respiratory System; Substance P; Vasoactive Intestinal Peptide | 1986 |
Non-adrenergic bronchodilatation.
Topics: Acetylcholine; Animals; Asthma; Bronchi; Humans; Lung; Nervous System; Neural Inhibition; Neurotransmitter Agents; Peptide PHI; Peptides; Protein Precursors; Purines; Respiratory System; Tissue Distribution; Vasoactive Intestinal Peptide | 1986 |
1 other study(ies) available for peptide-phi and Asthma
Article | Year |
---|---|
[Neuropeptides and respiratory diseases: prospects in the treatment of asthma].
The autonomic nervous system includes, side by side with the sympathetic and parasymathetic systems, a third, non-adrenergic and non-cholinergic system called NANC. The mediators in this system are peptides acting as neurotransmitters, i.e. neuropeptides. The NANC system has two components: bronchodilator and bronchoconstrictor. The bronchial relaxant system, called non-adrenergic inhibitory system, has several neurotransmitters, viz.: vasoactive intestinal peptide (VIP), isoleucine histidine peptide (IHP) and methionine histidine peptide (MPH), all derived from a common precursor: pre-pro VIP. MHP has been described in man and IHP in some animal species. VIP relaxes the bronchial smooth muscle, is vasodilator and exerts cellular effects in phagocytes, lymphocytes and mast cells. VIP receptors are present on cells. The other component, called non-cholinergic excitatory system, has tachykinins as neuromediators, including substance P, neurokinins A and B, neuropeptide K and calcitonin gene related peptide (CGRP). Substance P contracts the bronchi, increases mucus secretion, dilates vessels and also exerts cellular effects in lymphocytes and phagocytes. Tachykinins act through receptors 3 types of which are now known: NK 1, NK 2 and NK 3. Other neuropeptides have been isolated, including galanin, neuropeptide Y, bombesin, gastrin releasing peptide, enkephalins and katacalcin. The coexistence, in pre- and post-synaptic positions, of the conventional mediators (noradrenaline, acetylcholine) and neuropeptides leads to the concept of co-transmission and makes the notion of nerve impulse transmission more complex. The development of neuropeptide agonists and antagonists opens new therapeutic prospects in the management of asthma. Topics: Asthma; Bronchi; Calcitonin Gene-Related Peptide; Humans; Neuropeptides; Neurotransmitter Agents; Peptide PHI; Receptors, Neurotransmitter; Tachykinins; Vasoactive Intestinal Peptide | 1989 |